3 Top Healthcare Stocks to Buy for Growth and Dividends The healthcare sector has become a focal point for investors in 2024, offering an appealing mix of innovation-driven growth and reliable dividend income. In the past year, top-performing healthcare stocks in the S&P 500 Index ($SPX) have achieved remarkable gains, with DaVita Inc. (DVA) leading …
Continue reading “Top 3 Healthcare Stocks for Exceptional Growth and Reliable Dividends in 2024”
One Ultra-High-Yield Healthcare Stock to Buy Hand Over Fist and One to Avoid The healthcare sector isn’t typically the go-to choice for income investors looking for high dividend yields. In fact, when ranked among the 11 sectors of the S&P 500, healthcare comes in eighth place based on average dividend yield. Nonetheless, there are still …
Continue reading “One Must-Buy High-Yield Healthcare Stock and One to Steer Clear Of”
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks In mid-October, biotech stocks marked a significant recovery as they regained their 50-day moving average, propelled by encouraging results from Wave Life Sciences (WVE) in RNA editing. While the resurgence offers a glimmer of hope, it still falls short of the buoyant levels experienced …
Continue reading “Discover Top 5 Biotech Stocks Set to Outperform the Market in 2023”
Weight-Loss Medications Present New Hope Against Substance Abuse Recent findings suggest that weight-loss medications such as Ozempic and Wegovy may not only assist in weight management and diabetes control but could also play a significant role in reducing opioid and alcohol abuse. A noteworthy study published in the scientific journal Addiction indicates that these medications …
Continue reading “Weight-Loss Medications Show Promise in Reducing Opioid and Alcohol Abuse Rates”
Abbott Laboratories Surpasses Q3 Expectations and Optimizes Full-Year Forecast Abbott Laboratories, a key player in the healthcare products sector, reported robust third-quarter results on Wednesday, exceeding market expectations in both sales and earnings. This positive performance was largely attributed to the company’s thriving medical-devices division. The Abbott Park, Illinois-based company has also raised its earnings …
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar Earnings reports hold significant weight in the world of finance, and one number stands out above the rest: the earnings per share (EPS). This singular figure has the power to sway investors’ perceptions and trigger stock price movements. While Wall Street …
All Eyes on Medical Costs as UnitedHealth Reports Third-Quarter Results Investor Concerns Surrounding Healthcare Utilization When UnitedHealth Group, a prominent healthcare services firm, releases its third-quarter financial results early Tuesday, the key focus for investors will be the trend in medical services utilization among seniors. The health sector has been in turmoil following UnitedHealth’s fourth-quarter …
US FDA to Reconsider Decision Barring Compounded Versions of Lilly’s Weight Loss Drug The U.S. Food and Drug Administration (FDA) has made a significant decision to reconsider its previous ruling that restricted drug compounders from selling their own formulations of Eli Lilly’s (LLY.N) popular weight loss and diabetes drugs. This reconsideration comes in light of …
Upstream Bio and Two Other Biotech Startups Price Successful IPOs Amid Rising Healthcare Listings On Thursday, three U.S. healthcare startups successfully priced their initial public offerings (IPOs), showcasing a significant uptick in the sector’s activity. Leading the pack was Upstream Bio (UPB.O), raising an impressive $255 million at a valuation of approximately $830 million. This …
Continue reading “Upstream Bio Leads Surge of Biotech IPOs as Healthcare Sector Gains Momentum”
Viking Therapeutics Reports Positive Data in Trial for X-ALD Treatment Promising Results for VK0214 Viking Therapeutics Inc., a San Diego-based biopharmaceutical company, announced on Wednesday that it has achieved positive results from an early-stage trial for VK0214, a treatment aimed at the rare metabolic disorder X-linked adrenoleukodystrophy (X-ALD). X-ALD is a severe condition that usually …
